Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)








Dear Colleague Letters										Related Pages
										Return to Main Menu
**Venezuelan humanitarian relief program and TB testing**
November 17, 2022
Dear Colleagues,
This letter is to inform you of recent changes to how Venezuelans can legally enter the United States and the health requirements under the new migration enforcement program that went into effect last month.
**The Humanitarian Relief Program for Venezuelans**
On October 12, 2022, the U.S. Department of Homeland Security (DHS) announced Announcement | DHS a new process allowing Venezuelan nationals and their immediate family members to come to the United States. The process offers a way for Venezuelan nationals who are outside the United States and lack U.S. entry documents to be considered, on a case-by-case basis, for advance authorization to travel to the United States and a temporary period of parole for up to 2 years for urgent humanitarian reasons and significant public benefit. To participate in this process, Venezuelan nationals must have a sponsor in the United States and meet other requirements. The sponsors must apply to U.S. Citizenship and Immigration Services (USCIS), Process for Venezuelans | USCIS, and agree to provide the parole applicants with financial support for the duration of the parole. The program has a ceiling of 24,000 parolees.
**Attestation of Tuberculosis Testing and Vaccination under the Program**
The medical requirements are the same as they are for the Uniting for Ukraine Program and are available at Vaccine Attestation for Venezuelan Process | USCIS. Within 90 days of arrival, parolees who are aged 2 years and older must be tested for tuberculosis with an interferon-gamma release assay (IGRA) blood test and report the results to their “MyUSCIS” online accounts that they created while applying to the Humanitarian Relief Program for Venezuelans. In addition, all medically eligible applicants must receive at least one dose of a measles-containing vaccine, at least one dose of oral or intramuscular polio vaccine, and at least one dose of a COVID-19 vaccine prior to travel to the United States. After arriving in the United States, parolees must complete their primary COVID-19 series, if not done prior to arrival.
Venezuelan parolees may be referred to health departments for an IGRA test. If the health department cannot provide this test, please refer them to other resources. A tuberculin skin test will not be accepted in place of an IGRA.
**Tuberculosis in Venezuela**
Summarized in the World Health Organization’s Global Tuberculosis Report 2022 | WHO, the estimated national tuberculosis incidence rate in Venezuela in 2021 was 47/100,000 person-years, which incorporated an estimated case notification rate of 70%. The estimated proportion of cases with multidrug resistance was 3.4% among new cases and 15% among previously treated cases. These data might not be representative for Venezuelan parolees who are entering the United States under the new process.
**Drug Susceptibility Test Results for Venezuelans with Tuberculosis Reported in the United States**
For 2014–2021 in CDC’s National Tuberculosis Surveillance System, 119 cases of tuberculosis were reported in non–U.S.-born persons with Venezuela as the place of birth. Of these cases, 95 (80%) were culture confirmed, and 93 had susceptibility results for at least isoniazid and rifampin. Any isoniazid resistance was reported for 5 (5%), any rifampin resistance for 1 (1%), and multidrug resistance for none.
**Electronic Disease Notification System**
CDC’s Electronic Disease Notification System, EDN | CDC, does not have information about the Venezuelan parolees because they have not undergone the overseas immigration medical examination. Data from the attestation cannot be entered into EDN. The health requirements for parolees are not the same as those for the immigration medical examination for persons who are applying for adjustment of status, Technical Instructions for Civil Surgeons | CDC.
**Funding for Tuberculosis Testing and Other Health Services**
To date, the Office of Refugee Resettlement (ORR) in the Administration for Children and Families (ACF) and the Centers for Disease Control and Prevention (CDC) have not received funding designated for support of this program. The supplemental funds designated for Uniting for Ukraine under the CDC tuberculosis cooperative agreements may not be diverted for Venezuelan parolees. However, surplus supplies such as IGRA test kits may be used for the care of Venezuelan parolees if these supplies are not needed for Ukrainian parolees. Consult with your CDC project officer for the tuberculosis cooperative agreement before redirecting surplus supplies.
At this time, Venezuelan humanitarian parolees are not eligible for mainstream health benefits (Medicaid/CHIP) or benefits through ORR, including Refugee Medical Assistance (RMA) or the Domestic Medical Examination that would be recommended by CDC for ORR-eligible populations. For more information from ORR, see DCL 23-07: New USCIS Process for Venezuelans (hhs.gov). Health department personnel who provide tuberculosis testing may be the first point of contact with the U.S. healthcare system for Venezuelan parolees, and providers are encouraged to refer them to Federally Qualified Health Clinics or other local healthcare providers serving uninsured populations for basic healthcare. CDC is not collecting data from the health attestations or the IGRA results. We encourage you to collect information from tuberculosis testing and screening, consistent with your routine systems for migrant health, surveillance, and program management.
**Venezuelans Who Entered the United States before October 12, 2022**
Thousands of Venezuelans entered the United States this year before the parole program was started or were in the United States already under various visas. They presently do not have to meet the health requirements that apply to the parolees. Venezuelan nationals apprehended while attempting unauthorized entry across the southern land border into the United States after October 12, 2022 are being returned to Mexico, Announcement | DHS.
**Questions?**
If you have questions about the content of this letter, please contact Dr. John Jereb, mailto:jxj4@cdc.gov. For questions about your program operations and tuberculosis cooperative agreement, contact your project officer at the Division of Tuberculosis Elimination. For links to the network of refugee health, see State Refugee Health Coordinators.

Sincerely,
Terry Chorba
Terence Chorba, MD, DSc, FACP, FIDSA
Chief, Field Services Branch, Division of Tuberculosis Elimination
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
1600 Clifton Road NE (US 12-4), Atlanta, GA 30329
							
					
							Last Reviewed:  November 18, 2022						Source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue